

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midomafetamine,Ibogaine Hydrochloride,Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 3,4-methylenedioxymethamphetamine acts as a releaser of 5-HT and noradrenaline, and to a lesser extent also of dopamine. It is a potent empathogen-entactogen with stimulant properties primarily used for recreational purposes.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : Midomafetamine,Ibogaine Hydrochloride,Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ibogaine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A joint venture between DemeRx and Atai Life Sciences has been cleared by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start enrolment for a Phase I/IIa trial of ibogaine HCl (DMX-1002) in the treatment of opioid use disorder (OUD...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2021
Lead Product(s) : Ibogaine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ibogaine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Financing
ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder
Details : The investment aims at developing treatment protocol for safety of patients who are taking ibogaine for treatment of opioid use disorder (OUD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 24, 2020
Lead Product(s) : Ibogaine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Financing
